Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302

被引：0
|
作者：
Mainwaring, P. [1 ]
Yu, E. Y. [2 ]
Londhe, A. [3 ]
Van Poppel, H. [4 ]
Rathkopf, D. E. [5 ,6 ]
Smith, M. R. [7 ,8 ]
Souza, P. [9 ]
Griffin, T. W. [10 ]
Ryan, C. J. [11 ]
机构：
[1] Hematol & Oncol Clin Australia, Brisbane, Qld, Australia
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Janssen Res & Dev LLC, Raritan, NJ USA
[4] Katholieke Univ Leuven Hosp, Louvain, Belgium
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Weill Cornell Med Coll, New York, NY USA
[7] Harvard Univ, Sch Med, Boston, MA USA
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
[9] Univ Western Sydney, Sch Med, Sydney, NSW, Australia
[10] Janssen Res & Dev, Los Angeles, CA USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
来源：
BJU INTERNATIONAL | 2014年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
41
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [21] Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302
    de Bono, Johann S.
    Smith, Matthew R.
    Saad, Fred
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    Small, Eric J.
    Shore, Neal D.
    Fizazi, Karim
    De Porre, Peter
    Kheoh, Thian
    Li, Jinhui
    Todd, Mary B.
    Ryan, Charles J.
    Flaig, Thomas W.
    EUROPEAN UROLOGY, 2017, 71 (04) : 656 - 664
  • [22] The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score
    Miller, Kurt
    Carles, Joan
    Gschwend, Juergen E.
    Van Poppel, Hendrik
    Diels, Joris
    Brookman-May, Sabine D.
    EUROPEAN UROLOGY, 2018, 74 (01) : 17 - 23
  • [23] Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials.
    de Velasco, Guillermo
    Lora, David
    Lorente, David
    Choueiri, Toni K.
    Sweeney, Christopher
    Castellano, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [24] Updated interim analysis (IA) of COU-AA-302, a randomized phase III study of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy
    Rathkopf, Dana E.
    Smith, Matthew Raymond
    De Bono, Johann Sebastian
    Logothetis, Christopher
    Shore, Neal D.
    De Souza, Paul L.
    Fizazi, Karim
    Mulders, Peter
    Mainwaring, Paul N.
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott A.
    Fradet, Yves
    Griffin, Thomas W.
    Park, Youn Choi
    Kheoh, Thian San
    Small, Eric Jay
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [25] ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL
    Saad, Fred
    Shore, Neal D.
    Van Poppel, Hendrik
    Rathkopf, Dana
    Smith, Matthew R.
    de Bono, Johann S.
    Logothetis, Christopher
    de Souza, Paul
    Fizazi, Karim
    Mulders, Peter F. A.
    Mainwaring, Paul
    Hainsworth, John D.
    Beer, Tomasz M.
    North, Scott
    Fradet, Yves
    Griffin, Tom
    Kheoh, Thian
    Small, Eric J.
    Scher, Howard I.
    Molina, Arturo
    Ryan, Charles J.
    JOURNAL OF UROLOGY, 2013, 189 (04): : E293 - E293
  • [26] Clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis
    Aviles, C. M.
    Azad, A. A.
    Todenhoefer, T.
    Eigl, B. J.
    Kollmannsberger, C.
    Murray, N.
    Chi, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S486 - S487
  • [27] Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory post-hoc analysis of COU-AA-302 trial data.
    Pilon, Dominic
    Behl, Ajay S.
    Kamstra, Rhiannon
    Xiao, Yongling
    Lafeuille, Marie-Helene
    Lefebvre, Patrick
    Freedland, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] FINAL OVERALL SURVIVAL (OS) ANALYSIS OF COU-AA-302, A RANDOMIZED PHASE 3 STUDY OF ABIRATERONE ACETATE (AA) IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) WITHOUT PRIOR CHEMOTHERAPY
    Ryan, C. J.
    Smith, M. R.
    Fizazi, K.
    Miller, K.
    Mulders, P.
    Sternberg, C. N.
    Saad, F.
    Griffin, T.
    De Porre, P.
    Park, Y. C.
    Li, J.
    Kheoh, T.
    Naini, V.
    Molina, A.
    Rathkopf, D. E.
    ANNALS OF ONCOLOGY, 2014, 25
  • [29] Budget Impact of Enzalutamide for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Bui, Cat N.
    O'Day, Ken
    Flanders, Scott
    Oestreicher, Nina
    Francis, Peter
    Posta, Linda
    Popelar, Breanna
    Tang, Hong
    Balk, Mark
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (02): : 163 - U171
  • [30] Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Boegemann, Martin
    Hatzinger, Martin
    Hercher, Dirko
    Matus, Geoffrey
    Everaert, Els Grieta
    Dopchie, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345